NIH Director's New Innovator Award (DP2 Clinical Trial Optional)
Closed Posted
- Opportunity number
- RFA-RM-27-002
- Agency
-
National Institutes of Health
Department of Health and Human Services
- Applications due
- Award size
- $475,000
Opportunity facts
- Assistance listings
-
- 93.310 Trans-NIH Research Support
- Funding instrument
- Grant
- Category
-
- Health
- Eligible applicants
-
- County Governments
- City/Township Governments
- 501(c)(3) Nonprofits
- State Governments
- For Profit Organizations
- Tribal Organizations (Not Federally Recognized)
- Higher Education Inst. (Private)
- Small Businesses
- Special District Governments
- Non-501(c)(3) Nonprofits
- Public or Indian Housing Auth.
- Tribal Governments (Federally Recognized)
- Independent School Districts
- Higher Education Inst. (Public)
- Other
- Points of contact
Opportunity details come from Grants.gov. Updated .
About this opportunity
The National Institutes of Health is soliciting applications for the NIH Director's New Innovator Award (DP2 Clinical Trial Optional), a grant program supporting early-stage investigators proposing exceptionally creative and innovative biomedical research, with applications due July 17, 2026 by 5:00 PM local time. Applicants must meet Early Stage Investigator status, defined as having completed their terminal research degree or post-graduate clinical training within the past ten years without previously competing successfully for substantial NIH independent research awards, and must hold or commit to an independent research position at a domestic U.S. institution by September 1, 2027.
Eligible applicants include domestic higher education institutions (public and private), nonprofits (501(c)(3) and non-501(c)(3)), for-profit organizations, small businesses, state and local governments, tribal organizations (federally and non-federally recognized), and other domestic entities. Applications are limited to single Principal Investigator submissions, with individuals eligible to submit only one application per cycle. Applicants must commit a minimum of 25% effort annually to the award. No cost share is required.
The program anticipates approximately $23 million in funding for approximately thirty awards in fiscal year 2027. Individual awards provide up to $475,000 in direct costs per year plus applicable indirect costs for five-year project periods. The program welcomes applications in basic, translational, or clinical research across all biomedical science areas relevant to NIH's mission. Review emphasizes significance and potential impact, innovativeness of approaches, investigator qualifications demonstrating creativity, suitability of the award mechanism, and feasibility despite inherent risks. Preliminary data are not required but may be included. The program operates under CFDA 93.310 (Trans-NIH Research Support) and is a component of the NIH Common Fund's High-Risk, High-Reward Research program. Peer review is anticipated to conclude by March 2027, with awards beginning August 17, 2026.
Synopsis
The NIH Director"s New Innovator Award supports early-stage investigators of exceptional creativity who propose bold and highly innovative research projects with the potential to produce a major impact on broad, important areas relevant to the mission of NIH. Applications in any area within the biomedical sciences are welcome; topics may involve basic, translational, or clinical research. The NIH Director's New Innovator Award complements other ongoing efforts by NIH and its Institutes and Centers to fund early-stage investigators. The NIH Director"s New Innovator Award is a component of the High-Risk, High-Reward Research (HRHR) program of the NIH Common Fund.
Files
| File | Type | Posted |
|---|---|---|
| RFA-RM-27-002-Full-Announcement.html | HTML file |
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar grant opportunities
- Ask GovTribe AI about this opportunity